RecruitingPhase 1NCT07004244

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies

Sponsor

Sichuan University

Enrollment

20 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Tumors

Summary

The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called KRAS-mutated mRNA vaccine, a drug called Pemetrexed+carboplatin, and others for people with malignant tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALKRAS-mutated mRNA vaccine

Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose. Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery

BIOLOGICALTORIPALIMAB

intravenous injection

DRUGPemetrexed+carboplatin

intravenous injection